Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Hansa Biopharma AB, retaining the price target of SEK103.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors that, in his view, outweigh the weak first-quarter results. He attributes the soft Q1 revenue mainly to the restructuring of Hansa Biopharma’s European commercial organization and the inherent volatility in organ allocation, and views these as temporary rather than structural issues.
Tsao expects a rebound starting in the second quarter, supported by newly secured reimbursement in Catalonia, a historically important region for patient access. He also highlights upcoming German clinical guidelines, pivotal PAESE study data for converting conditional EU approval to full approval, and expanding real‑world evidence, all of which he believes should unlock additional markets and drive stronger, more sustainable long‑term sales growth.
Tsao covers the Healthcare sector, focusing on stocks such as Xenon, Protagonist Therapeutics, and Roivant Sciences. According to TipRanks, Tsao has an average return of 19.6% and a 51.00% success rate on recommended stocks.